Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxytocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 12/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 6/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 5/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytocin SCHEMBL1173243 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL14085374 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL8370159 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL2126148 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL5110121 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL1661474 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL19303330 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 49125 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146967-A1 | DEVICE AND SENSOR FOR DETECTION OF AN ANALYTE | REMINDED, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | MANNKIND CORPORATION (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-116698563-B | Method for detecting polypeptide by capillary gel electrophoresis | ZHEJIANG UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137727-A1 | PREVENTION AND TREATMENT OF KIDNEY FAILURE BY ADMINISTRATION OF FIBROBLASTS AND PRODUCTS THEREOF | SPINALCYTE LLC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026101401-A1 | METHODS AND MEANS OF TREATING MENTAL DISORDERS | IP HELICUS HOLDING B.V. (NL) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739283-A1 | PEPTIDE STEREOCOMPLEXATION WITH BIODEGRADABLE STEREOREGULAR POLYESTERS IN WATER AND HYDROGEL FORMS THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2026-05-13 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| EP-0092708-A2 | Composite article for the sustained release of active agents | Akzo GmbH (DE) | 1983-11-02 | — | — | EP | claimed |
| EP-0092918-A2 | Continuous release formulations | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-11-02 | — | — | EP | claimed |
| US-4402942-A | MUSCLE RELAXANT | FERRING AB (SE) | 1983-09-06 | — | — | US | claimed |
| US-4392996-A | DISPLACEMENT OF NEUROPEPTIDE ANALOG FROM BRAIN OR OTHER ORGAN BY NEUROPEPTIDE | THE UNIVERSITY OF ROCHESTER (US) | 1983-07-12 | — | — | US | claimed |
| US-4216141-A | OXIDATION OF CYSTEINE RESIDUES TO FORM DISULFIDE BOND | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1980-08-05 | — | — | US | claimed |
| EP-0010587-A1 | Adamantylalkyloxy-carbonyl derivatives, their preparation and their use for the production of peptides | Kalbacher, Hubert (DE) | 1980-05-14 | — | — | EP | claimed |
| US-4033940-A | TERMINAL CYSTINE, REARRANGEMENT TO CYCLIC DISULFIDE | ARMOUR PHARMACEUTICAL COMPANY (US) | 1977-07-05 | — | — | US | claimed |
| US-4005200-A | DEHYDROEPIANDROSTERONE SULFATE OR SALTS | KANEBO, LTD. (JA) | 1977-01-25 | — | — | US | claimed |
| US-3943246-A | ADMINISTERING OXYTOCIN OR DESAMINO-OXYTOCIN TO TREAT MALE IMPOTENCY | SANDOZ LTD. (CH) | 1976-03-09 | — | — | US | claimed |